133 related articles for article (PubMed ID: 483251)
1. Immunohistochemical and histochemical investigations on in vivo thrombolysis with urokinase in rabbits.
Hisano S; Sueishi K; Ishii Y; Tanaka K
Thromb Haemost; 1979 Jun; 41(4):796-803. PubMed ID: 483251
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
3. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
4. Vasodilation, fibrinolysis, and thrombolysis with intraarterial infusion of urokinase in the canine superior mesenteric artery.
Gurll N; Zinner MJ; Turtinen L; Reynolds DG
Gastroenterology; 1978 Sep; 75(3):425-31. PubMed ID: 98390
[TBL] [Abstract][Full Text] [Related]
5. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
Lipinski B; Gurewich V; Hyde E
Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
[No Abstract] [Full Text] [Related]
6. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
[No Abstract] [Full Text] [Related]
7. Immunofluorescence study on thrombolysis with special reference to the patterns of distribution and the contents of fibrin, plasminogen, alpha2-macroglobulin and urokinase in artificial thrombi.
Hisano S
Thromb Haemost; 1978 Feb; 39(1):53-60. PubMed ID: 77051
[TBL] [Abstract][Full Text] [Related]
8. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
Thorsen S; Astrup T
Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113
[No Abstract] [Full Text] [Related]
9. Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
Kodama Y; Tanaka K
Gan; 1978 Feb; 69(1):9-18. PubMed ID: 640328
[TBL] [Abstract][Full Text] [Related]
10. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
11. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen-fibrin related antigen pattern in human blood. Incomplete lysis of whole blood clots by urokinase.
Jacobsen CD; Fry GL; Wu KK; Southers NJ
Thromb Res; 1975 Apr; 6(4):327-36. PubMed ID: 1079637
[No Abstract] [Full Text] [Related]
13. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
14. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
[TBL] [Abstract][Full Text] [Related]
15. [In vitro measurement of fibrinolysis by urokinase].
Senf L
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):819-21. PubMed ID: 6176506
[TBL] [Abstract][Full Text] [Related]
16. Effect of urokinase on fibrinolysis and fibrinogenolysis.
Matsuo O; Nishida Y; Akazawa K; Mihara H
Jpn J Physiol; 1982; 32(5):879-83. PubMed ID: 6759739
[TBL] [Abstract][Full Text] [Related]
17. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
Thorsen S
Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
[No Abstract] [Full Text] [Related]
18. [Low molecular weight heparin and high and low molecular weight urokinase in fibrinolysis in vivo].
Badimón L; Villaverde CA; Vidal M; Valdecasas FG
Arch Farmacol Toxicol; 1979 Dec; 5(3):262-4. PubMed ID: 397803
[No Abstract] [Full Text] [Related]
19. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
Bode C; Eberle T; Runge M; Haber E; Kübler W
Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
[No Abstract] [Full Text] [Related]
20. An artificial circulation for the study of thrombolysis. The influence of flow rate and pressure on thrombolysis and a comparison between urokinase and tissue activator as thrombolytic agents.
Walker JE; Flook V; Ogston D
Acta Haematol; 1983; 69(1):41-6. PubMed ID: 6401892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
